Feb 27, 2026 | CagriSema's New Story After REDEFINE 4, GSK's $950M Activin Bet, Lilly Wins ACHIEVE-3

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

Novo's CagriSema misses non-inferiority against Zepbound in REDEFINE 4 — approval path intact,differentiation argument shifts to outcomes data. GSK pays $950M for HS235 (35Pharma), a Phase 1 activin inhibitor targeting Merck's Winrevair territory.Lilly's ACHIEVE-3 puts orforglipron decisively ahead of oral semaglutide: 31.4% of patients to near-normal A1C vs 11.7%. Two FDA decisions today: TransCon CNP for achondroplasia and Dupixent's AFRS label expansion.

Episode metadata supplied by the publisher feed · Published Mar 3, 2026

Embed this episode

Attribution link and audio player

Ready to play

Feb 27, 2026 | CagriSema's New Story After REDEFINE 4, GSK's $950M Activin Bet, Lilly Wins ACHIEVE-3

0:00 10:02

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 10 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on March 3, 2026.

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!